Sarcoidosis management

Sarcoidosis is a multisystem granulomatous disease that most often affects the lungs, presenting a wide range of clinical manifestations from incidental radiographic findings to severe respiratory impairment. The unpredictable nature of the disease requires individualized approaches, as some cases spontaneously resolve while others progress to chronic forms leading to fibrosis. The cornerstone of sarcoidosis management is the use of corticosteroids to reduce granulomatous inflammation, but prolonged steroid therapy carries significant side effects. For patients who require long-term treatment, steroid-sparing agents such as methotrexate, azathioprine, and leflunomide are frequently employed. In refractory cases, biologic agents targeting tumor necrosis factor-alpha and other immune pathways are providing new avenues for control. Clinicians also emphasize monitoring extrapulmonary involvement, including cardiac and neurological manifestations, which can significantly affect prognosis. Regular imaging, pulmonary function testing, and biomarker evaluation help guide therapeutic decisions and track disease progression. Supportive care, including pulmonary rehabilitation and patient education, improves quality of life and fosters adherence. Increasing research into genetic predispositions, environmental triggers, and immune mechanisms promises to refine diagnostic precision and expand treatment choices. The evolving strategies in sarcoidosis management highlight the importance of a multidisciplinary framework that balances pharmacological intervention with supportive measures, aiming to preserve lung function, minimize long-term complications, and enhance patient well-being.